A groundbreaking medication, Retatrutide , is sparking considerable excitement amongst healthcare professionals and patients in Australia dealing with obesity . Manufactured by Eli Lilly , Retatrutide operates as a dual GIP and GLP-1 receptor-based agonist, displaying remarkable potential to supp… Read More